Safety of Prescribing Statins in Childhood DyslipidemiaFunding None.
Hyperlipidemia is on the rise in pediatrics, leading to early coronary artery disease complications. Familial hypercholesterolemia is an important risk factor, with the homozygous subtype being more dangerous, yet less prevalent than the heterozygous subtype. Statins are shown to be an effective treatment in this population. This systematic review will emphasize the safety of such drug class in pediatrics, while taking into consideration the latest cholesterol guideline. Cochrane Library, Clinicaltrials.gov, and PubMed were reviewed systematically in June 2019 and rechecked in November 2019 for the past 5 years with keywords like child, safety, hyperlipidemia, and statins, which resulted in nine randomized clinical trials. In short, statins are shown to be intermediately effective—median decrease of low-density lipoprotein cholesterol was 32% achieving the target of < 160 mg/dL in 67% of patients—in lowering lipid levels yet preventing early complications. They are also considered safely tolerated in most cases, even when taken for extended periods, but still not evidently permissible for children below 8 years old, which was the average age of all participants in the trials. Statins should not be given generally for pediatrics of less than 8 years old, in contrast to what was mentioned in the American Heart Association guideline (0–19 age range), since there is no evidence supporting their safety within this age group.
The article is not submitted to any other media, has not been published earlier, all its authors have read and approved the manuscript, and all its authors are responsible for the reliability of the materials presented.
Received: 06 May 2020
Accepted: 11 August 2020
01 October 2020 (online)
Georg Thieme Verlag KG
Stuttgart · New York
- 1 Lozano P, Henrikson NB, Morrison CC. et al. Lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016; 316 (06) 634-644
- 2 Joyce N, Wellenius GA, Dore DD, Newburger JW, Zachariah JP. Patterns of lipid lowering therapy among children ages 8–20 years. J Pediatr 2015; 167 (01) 113-9.e1
- 3 Stein EA, Dann EJ, Wiegman A. et al. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J Am Coll Cardiol 2017; 70 (09) 1162-1170
- 4 Langslet G, Breazna A, Drogari E. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. J Clin Lipidol 2016; 10 (05) 1153-1162.e3
- 5 Harada-Shiba M, Ohta T, Ohtake A. Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia. et al. Guidance for pediatric familial hypercholesterolemia 2017. J Atheroscler Thromb 2018; 25 (06) 539-553 DOI: 10.5551/jat.CR002.
- 6 Obiorah C. Cardiovascular System Mortalities in Nigeria; Case Study of the University of Port Harcourt Teaching Hospital. World Journal of Cardiovascular Diseases 2019; 9: 867-878 DOI: 10.4236/wjcd.2019.912077.
- 7 Vuorio A, Kuoppala J, Kovanen PT. et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2017; 7 (07) CD006401
- 8 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; Nov 10:[Epub ahead of print]
- 9 Molven I, Retterstøl K, Andersen LF. et al. Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children. J Nutr Sci 2013; 2: e32
- 10 Cicero AFG, Fogacci F, Giovannini M, Bove M, Debellis G, Borghi C. Effect of quantitative and qualitative diet prescription on children behavior after diagnosis of heterozygous familial hypercholesterolemia. Int J Cardiol 2019; 293: 193-196
- 11 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 (05) 213-256
- 12 Mamann N, Lemale J, Karsenty A, Dubern B, Girardet JP, Tounian P. Intermediate-term efficacy and tolerance of statins in children. J Pediatr 2019; 210: 161-165
- 13 Eiland LS, Luttrell PK. Use of statins for dyslipidemia in the pediatric population. J Pediatr Pharmacol Ther 2010; 15 (03) 160-172
- 14 Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011; 10 (03) 373-387
- 15 Domingo K, Grossman D, Curry S. et al. Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. JAMA 2016; 316 (06) 625-633
- 16 Wagner J, Abdel-Rahman SM. Pediatric statin administration: navigating a frontier with limited data. J Pediatr Pharmacol Ther 2016; 21 (05) 380-403
- 17 Braamskamp MJ, Kusters DM, Avis HJ. et al. Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Paediatr Drugs 2015; 17 (02) 159-166
- 18 Braamskamp MJ, Kusters DM, Wiegman A. et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood. Atherosclerosis 2015; 241 (02) 427-432
- 19 Harada-Shiba M, Kastelein JJP, Hovingh GK. et al. Efficacy and safety of pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe. J Atheroscler Thromb 2018; 25 (05) 422-429
- 20 Vuorio A, Kuoppala J, Kovanen PT. et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2019; 2019 (11) CD006401
- 21 Wassif CA, Kratz L, Sparks SE. et al. A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome. Genet Med 2017; 19 (03) 297-305
- 22 Hari P, Khandelwal P, Satpathy A. et al. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial. Pediatr Nephrol 2018; 33 (12) (Suppl. 05) 2299-2309
- 23 Braamskamp MJ, Stefanutti C, Langslet G. PASCAL Study Group. et al. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. J Pediatr 2015; 167 (02) 338-43.e5
- 24 Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 2007; 120 (01) e189-e214
- 25 Harada-Shiba M, Arisaka O, Ohtake A, Okada T, Suganami H. NK-104-PH 01 study registration group. Efficacy and safety of pitavastatin in Japanese male children with Familial Hypercholesterolemia. J Atheroscler Thromb 2016; 23 (01) 48-55
- 26 Juhola J, Magnussen CG, Viikari JS. et al. Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. J Pediatr 2011; 159 (04) 584-590